StreetAlpha.app
Home › Stocks › TXG

10x Genomics, Inc. (TXG)

Healthcare
$56.30
▲ +2.38%
LAST CLOSE · NOV 17

10x Genomics makes instruments, consumables and software for studying biology at the single cell and tissue level. It last closed at $56.30 on Nov 17, up 2.38% on the day. TXG reports earnings on Thu, Feb 11, 2027. The average 12-month price target from 12 analysts is $76.17 (+35.3% from the last close), with a high of $110.00 and a low of $60.00. Analyst consensus is Hold, based on the latest ratings from 12 firms (4 buy, 8 hold, 0 sell). Over the past 90 days StreetAlpha recorded 3 whale options trades in TXG, 100% of them bullish and 0% bearish. In the past 30 days there were 3 dark pool prints totaling $2.2M, the largest $934K.

AI Auto Pilots
Is TXG in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$618.6M
−3.6% vs a year ago
Net income
−$67.1M
−10.8% margin
EPS (diluted)
−$0.52
Free cash flow
$93.8M
15.2% margin
Balance sheet
Cash & equivalents
$526.2M
At Sep 30
Shareholder equity
$838.0M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $490.5M$490.5MFY2021FY2022: $516.4M$516.4MFY2022FY2023: $618.7M$618.7MFY2023FY2024: $610.8M$610.8MFY2024FY2025: $642.8M$642.8MFY2025

From TXG's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 6). Last 12 months adds up the four latest quarters.

Next report
Feb 11
2027 · Time not announced
Consensus EPS forecast
-$0.20
$177.7M revenue est.
Year-ago EPS
$0.07
Same quarter last year
Options-implied move
—
Posted about a week before
Analyst consensus
Hold
Based on 12 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Hold
12firms
4 Buy8 Hold0 Sell
Each firm's latest rating on TXG in the past 90 days
Average 12-month target
$76.17
▲ 35.3% upside

Based on 12 analysts who set a price target on TXG in the past 90 days. The average target is $76.17, with a high of $110.00 and a low of $60.00, compared with the last close of $56.30.

Low $60.00Avg $76.17High $110.00
Blue marker: last close $56.30
Highest target$110.00
Average target$76.17
Lowest target$60.00
Latest rating changes
JP MorganMaintained
Nov 9Hold$65
BarclaysTarget lowered
Nov 9Buy$110 → $70
UBSTarget lowered
Nov 6Hold$68 → $61
CitigroupTarget raised
Nov 6Hold$50 → $60
StifelMaintained
Nov 6Buy$68
DateFirmActionRatingPrice target
Nov 9JP MorganMaintainedHold$65
Nov 9BarclaysTarget loweredBuy$110 → $70
Nov 6UBSTarget loweredHold$68 → $61
Nov 6CitigroupTarget raisedHold$50 → $60
Nov 6StifelMaintainedBuy$68
Loading…

Technical Analysis

TXG · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend

The stock is 18% below its 20 day and 31% below its 50 day average. It is 24% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 38). The nearest support is the swing low (Nov 6) at $55.50, and the nearest resistance the Pivot R1 at $57.80.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 11.3%/day
Key levels
$102.8152 week high+82.6%
$73.5850 day average+30.7%
$66.6820 day average+18.4%
$62.52100 day average+11.0%
$60.69Swing high (Aug 11)+7.8%
$57.80Pivot R1+2.7%
$56.30Last close
$55.50Swing low (Nov 6)−1.4%
$55.23Pivot−1.9%
$53.74Pivot S1−4.5%
$42.93200 day average−23.7%
$15.1852 week low−73.0%
Indicators
RSI (14)38.46Weak, oversold below 30Neutral
MACD-4.73Below its signal lineBearish
Stochastic10.7Near the bottom of its rangeOversold
ADX (14)20.5Weak trend
Williams %R-88.6Oversold below −80, overbought above −20Oversold
CCI (20)-111.4Oversold below −100, overbought above 100Oversold
Rate of change−13.8%Change over 10 sessionsBearish
ATR (14)$6.35Typical daily range, 11.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for TXG

What happened before

See how TXG did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow leans bullish3 bullish and 0 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow TXG usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How TXG has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
3
Bullish
3
100%
Bearish
0
0%
Date span
Oct 28 – Nov 3
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
3
Notional
$2.2M
Largest print
$934K
Loading…

TXG Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●260 buying vs 238 selling
  • ▲Shares held by funds +1.2%
  • ▲Funds holding +98
  • ▼Superinvestors: 3 added, 5 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding492394+24.9%
In funds' top 1085+60.0%
Held by funds–––
New / increased153 / 10797 / 97+34.0%
Reduced / sold out188 / 50141 / 33+36.8%
Put/call ratio1.120.51+121.2%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TXG institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TXG is in one of them and how their past TXG trades turned out.

TXG in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TXG in an article yet. Here's the latest on the wider market.

About 10x Genomics

10x Genomics is a life sciences technology company based in Pleasanton, California. It makes instruments, consumables and software that help researchers study biology at the level of single cells and within tissue samples. Its main product lines are the Chromium platform for single cell analysis and the Visium and Xenium platforms for spatial analysis. Its customers include academic, government and biopharmaceutical institutions focused on life sciences research, and it sells its products worldwide.

Headquarters
Pleasanton, CA